BioCentury | Apr 11, 2011
Company News

Intrinsiq Materials Ltd., Nanoco Technologies Ltd., Senexis, Sterlin Ltd., National Physical Laboratory, University College London, University of Leeds diagnost

...award will support three diagnostic projects, including funding to the U.K.'s National Physical Laboratory and Senexis...
...were not disclosed. Intrinsiq Materials Ltd. , Farnborough, U.K. Nanoco Technologies Ltd. , Manchester, U.K. Senexis Ltd....
BioCentury | May 31, 2010
Company News

Senexis, The Wellcome Trust neurology news

...London, U.K.) in 2006. Senexis received the award in 2008 (see BioCentury, Jan. 21, 2008). Senexis Ltd....
BioCentury | Apr 26, 2010
Finance

The bite of reform

...bacterial infections Undisclosed Pentraxin Therapeutics Ltd. £3.9 $6.0 Compounds to treat systemic transthyretin amyloidosis Discovery Senexis Ltd....
BioCentury | Apr 1, 2010
Targets & Mechanisms

Affibody vs Amyloid

...and Dobson. Andrew Doig, professor of biochemistry at The University of Manchester and cofounder of Senexis Ltd....
...to an albumin-binding domain had 25-fold lower plasma clearance than a nonfused Affibody. 4 Nonetheless, Senexis...
...designed to target Ab are very useful for mechanistic studies of amyloid aggregation pathways," said Senexis...
BioCentury | Jun 19, 2008
Distillery Techniques

This Week in Techniques

...associated with amyloid diseases. Work on N-methylated peptides for amyloid inhibition is patented; licensed to Senexis Ltd....
BioCentury | Feb 18, 2008
Company News

Oxygen Healthcare Ltd., Senexis deal

...Oxygen Healthcare will provide synthetic and computational chemistry services for Senexis’ drug discovery programs to treat...
...diabetes and dialysis-related amyloidosis. Financial terms were not disclosed. Oxygen Healthcare Ltd. , Cambridge, U.K. Senexis Ltd....
BioCentury | Jan 21, 2008
Company News

Senexis, The Wellcome Trust neurology news

...Feb. 6, 2006). The Wellcome Trust had previously invested £2.4 million ($4.7 million) in Senexis. Senexis Ltd....
BioCentury | Jan 22, 2007
Company News

DanioLabs, Senexis deal

...DanioLabs will use its zebrafish technology to screen Senexis' preclinical small molecules for Alzheimer's disease (AD...
...molecules for Alzheimer's disease (AD). Further details were not disclosed. DanioLabs Ltd. , Cambridge, U.K. Senexis Ltd....
BioCentury | Feb 6, 2006
Company News

BTG, Senexis deal

...BGC granted Senexis an exclusive license to preclinical compounds that inhibit amyloid-induced toxicity and neuroinflammation to...
...and the Wellcome Trust each invested £500,000 ($884,000) in Senexis. BTG plc (LSE:BGC), London, U.K. Senexis Ltd....
BioCentury | Feb 3, 2006
Company News

BTG, Senexis AD deal

...BTG (LSE:BGC) granted Senexis ( Cambridge , U.K.) an exclusive license to undisclosed preclinical inhibitors of...
...$884,000) in Senexis . The parties invested a total of L1.4 million ($2.2 million) in Senexis...
Items per page:
1 - 10 of 16
BioCentury | Apr 11, 2011
Company News

Intrinsiq Materials Ltd., Nanoco Technologies Ltd., Senexis, Sterlin Ltd., National Physical Laboratory, University College London, University of Leeds diagnost

...award will support three diagnostic projects, including funding to the U.K.'s National Physical Laboratory and Senexis...
...were not disclosed. Intrinsiq Materials Ltd. , Farnborough, U.K. Nanoco Technologies Ltd. , Manchester, U.K. Senexis Ltd....
BioCentury | May 31, 2010
Company News

Senexis, The Wellcome Trust neurology news

...London, U.K.) in 2006. Senexis received the award in 2008 (see BioCentury, Jan. 21, 2008). Senexis Ltd....
BioCentury | Apr 26, 2010
Finance

The bite of reform

...bacterial infections Undisclosed Pentraxin Therapeutics Ltd. £3.9 $6.0 Compounds to treat systemic transthyretin amyloidosis Discovery Senexis Ltd....
BioCentury | Apr 1, 2010
Targets & Mechanisms

Affibody vs Amyloid

...and Dobson. Andrew Doig, professor of biochemistry at The University of Manchester and cofounder of Senexis Ltd....
...to an albumin-binding domain had 25-fold lower plasma clearance than a nonfused Affibody. 4 Nonetheless, Senexis...
...designed to target Ab are very useful for mechanistic studies of amyloid aggregation pathways," said Senexis...
BioCentury | Jun 19, 2008
Distillery Techniques

This Week in Techniques

...associated with amyloid diseases. Work on N-methylated peptides for amyloid inhibition is patented; licensed to Senexis Ltd....
BioCentury | Feb 18, 2008
Company News

Oxygen Healthcare Ltd., Senexis deal

...Oxygen Healthcare will provide synthetic and computational chemistry services for Senexis’ drug discovery programs to treat...
...diabetes and dialysis-related amyloidosis. Financial terms were not disclosed. Oxygen Healthcare Ltd. , Cambridge, U.K. Senexis Ltd....
BioCentury | Jan 21, 2008
Company News

Senexis, The Wellcome Trust neurology news

...Feb. 6, 2006). The Wellcome Trust had previously invested £2.4 million ($4.7 million) in Senexis. Senexis Ltd....
BioCentury | Jan 22, 2007
Company News

DanioLabs, Senexis deal

...DanioLabs will use its zebrafish technology to screen Senexis' preclinical small molecules for Alzheimer's disease (AD...
...molecules for Alzheimer's disease (AD). Further details were not disclosed. DanioLabs Ltd. , Cambridge, U.K. Senexis Ltd....
BioCentury | Feb 6, 2006
Company News

BTG, Senexis deal

...BGC granted Senexis an exclusive license to preclinical compounds that inhibit amyloid-induced toxicity and neuroinflammation to...
...and the Wellcome Trust each invested £500,000 ($884,000) in Senexis. BTG plc (LSE:BGC), London, U.K. Senexis Ltd....
BioCentury | Feb 3, 2006
Company News

BTG, Senexis AD deal

...BTG (LSE:BGC) granted Senexis ( Cambridge , U.K.) an exclusive license to undisclosed preclinical inhibitors of...
...$884,000) in Senexis . The parties invested a total of L1.4 million ($2.2 million) in Senexis...
Items per page:
1 - 10 of 16